Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
28,593,359
-
Share change
-
+4,884
-
Total reported value
-
$384,023,894
-
Put/Call ratio
-
94%
-
Price per share
-
$13.43
-
Number of holders
-
142
-
Value change
-
+$1,477,688
-
Number of buys
-
76
-
Number of sells
-
63
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q1 2023
As of 31 Mar 2023,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,593,359 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, Nuveen Asset Management, LLC, GOLDMAN SACHS GROUP INC, Rockefeller Capital Management L.P., PICTET ASSET MANAGEMENT SA, and MACQUARIE GROUP LTD.
This page lists
142
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.